Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9529134 | 0.82 | CA1 (0.53) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL29550577 | 0.81 | CA1 (0.47) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL1615851 | 0.81 | CA1 (0.47) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL30884944 | 0.80 | CA1 (0.46) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL16217150 | 0.80 | CA1 (0.47) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL3163274 | 0.80 | CXCR2 (0.53) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL6229624 | 0.80 | CA1 (0.42) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL9915908 | 0.79 | TDP1 (0.53) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL30884943 | 0.79 | ALDH1A1 (0.44) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL8875737 | 0.79 | MAPK1 (0.47) | TDP1CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240543-B1 | BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| EP-2948458-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20180118766-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-03 | — | — | US | disclosed |
| EP-3240543-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| US-9481682-B2 | Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| WO-2016109216-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20150353570-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2948458-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014114185-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| US-20140206681-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. | 2014-07-24 | — | — | US | disclosed |
| US-6677288-B2 | ORGANIC SUBSTANCE, ESPECIALLY A N-(3-AMINO-PROPYL)-6-(((DI-PYRIDIN-2-YL-METHYL)-PYRIDIN-2-YLMETHYL-AMINO) -METHYL) LIGAND THAT FORMS A COMPLEX WITH A TRANSITION METAL; COMPLEX IS BOUND TO A RECOGNIZING PORTION | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| EP-1285055-B1 | TARGETED MOIETIES FOR USE IN BLEACH CATALYSTS | UNILEVER PLC (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2003070732-A1 | FUSED BICYCLIC-N-BRIDGED-HETEROAROMATIC CARBOXAMIDES FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003068230-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
| CN-1432059-A | Targeted moieties for use in blech catalysts | UNILEVER PLC (NL) | 2003-07-23 | — | — | CN | disclosed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| EP-1285055-A1 | TARGETED MOIETIES FOR USE IN BLEACH CATALYSTS | UNILEVER PLC (GB) | 2003-02-26 | — | — | EP | disclosed |
| US-20020049146-A1 | Targeted moieties for use in bleach catalysts | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-04-25 | — | — | US | disclosed |
| WO-2001092455-A1 | TARGETED MOIETIES FOR USE IN BLEACH CATALYSTS | UNILEVER PLC (GB) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | NAT1, CYP11B1, COASY | TDP1 2111/4885CA1 871/4885CA2 1044/4885 |
| US-20180118766-A1 | BTK INHIBITORS | BTK, SYK, LYN | TDP1 611/4885CA1 4843/4885CA2 3100/4885 |
| US-20140206681-A1 | BTK INHIBITORS | BTK, SYK, LYN | TDP1 548/4885CA1 4747/4885CA2 2058/4885 |
| US-20150353570-A1 | BTK INHIBITORS | BTK, SYK, LYN | TDP1 548/4885CA1 4747/4885CA2 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.